The results of the phase III ToGA trial (Bang et al, 2010) indicate trastuzumab plus cisplatin and fluoropyrimidine chemotherapy as the standard of care for patients with HER2-positive advanced gastric cancers. This evidence concerns the gene ERBB2 and gastric cancer.